.
MergerLinks Header Logo

New Deal


Announced

Medipost to acquire a 39.6% stake in OmniaBio for C$30m.

Synopsis

Medipost, a Korea-based stem cell biotechnology company, agreed to acquire a 39.6% stake in OmniaBio, a contract development and manufacturing company for cell and gene therapy products, for C$30m ($24m). “OmniaBio, a verified CDMO company for cell and gene therapy products, needed to expand its business to Asia, and our company had an eye on the North American market for our CDMO business. This investment went through seamlessly because the two companies had the same intentions," Medipost.

Show Details & Financials

Market Context

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US